By Karen Roman
Diagnostics company SkylineDx said it will present clinical data on the success of its Merlin test at the 21st International Congress of the Society for Melanoma Research 2024 in New Orleans.
The CP-GEP Merlin test accurately stratifies T1a melanoma patients considered for lymph node biopsy according to their risk, decreasing surgeries by 87.6% with a negative predictive value of 98.5%, it said.
“The intent is to help prevent undertreatment in seemingly low-risk early-stage melanoma patients who are actually at risk for nodal metastasis,” said Alexander Meves, MD, principal inventor of the CP-GEP model. “By accurately identifying these at-risk individuals, we ensure that they receive the necessary interventions, even in the absence of traditional clinical risk factors.”
Contact:
Exec Edge
Editor@executives-edge.com